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Abstract
Use of amphetamine and methamphetamine is widespread in the general population and common among
patients with psychiatric disorders. Amphetamines may induce symptoms of psychosis very similar to those of
acute schizophrenia spectrum psychosis. This has been an argument for using amphetamine-induced psychosis as
a model for primary psychotic disorders. To distinguish the two types of psychosis on the basis of acute symptoms
is difficult. However, acute psychosis induced by amphetamines seems to have a faster recovery and appears to
resolve more completely compared to schizophrenic psychosis. The increased vulnerability for acute amphetamine
induced psychosis seen among those with schizophrenia, schizotypal personality and, to a certain degree other
psychiatric disorders, is also shared by non-psychiatric individuals who previously have experienced
amphetamine-induced psychosis. Schizophrenia spectrum disorder and amphetamine-induced psychosis are further
linked together by the finding of several susceptibility genes common to both conditions. These genes probably
lower the threshold for becoming psychotic and increase the risk for a poorer clinical course of the disease.
The complex relationship between amphetamine use and psychosis has received much attention but is still not
adequately explored. Our paper reviews the literature in this field and proposes a stress-vulnerability model for
understanding the relationship between amphetamine use and psychosis.
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Background
Amphetamine and methamphetamine (hereafter amphe-
tamines) can prolong wakefulness, increase focus and
feelings of energy as well as decrease fatigue. They can
produce euphoria, induce anorexia, and be used to treat
narcolepsy and attention deficit/hyperactivity disorder
(ADHD). Adverse effects include anxiety, aggression,
paranoia, hyperactivity, reduced appetite, tachycardia,
increased breathing rate, dilated pupils, increased blood
pressure, headache, insomnia, palpitations, arrhythmia
and others [1].
Amphetamines inhibit dopamine reuptake by interact-
ing with the dopamine transporter (DAT), thereby in-
creasing the concentration of dopamine in the synaptic
cleft [2]. Amphetamines also interact with the vesicular
monoamine transporter 2 (VMAT2), leading to increas-
ing amounts of dopamine in the cytosol, a possible
mechanism of action for the neurotoxicity of ampheta-
mines. Neurotoxic effects are seen also in serotonergic
and noradrenergic neurons.
Amphetamines are highly addictive drugs. Both am-
phetamine and methamphetamine act directly on the
mesolimbic dopaminergic “reward system” [3] by indu-
cing release of dopamine, and to some extent norepin-
ephrine, in the synaptic clefts of the Nucleus
Accumbens (NAc) and other terminal areas provoking a
euphoric state, but also addiction.
Abuse of amphetamines is widespread in the general
population [4-9]. It is also common among psychiatric
patients [10,11], where a high percentage test positive
for amphetamines [12].
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There is overwhelming evidence that patients with
psychotic disorders have an increased vulnerability to
compulsive use of drugs of abuse [13,14], including psy-
cho stimulants like amphetamines [15]. This may be
especially true for patients with schizophrenia like disor-
ders [16]. There may be several explanations for this
increased co morbidity, but there is convincing evidence
from animal studies that this may be due to shared vul-
nerabilities for both psychosis and drug use disorders
[17]. These animal studies also point to possible neural
mechanisms explaning the increased co morbidity [18].
The association between amphetamine use and psych-
osis has received much attention [19], but several ques-
tions about this complex relationship remain unanswered.
In the following, we review some of these questions and
propose a new model for understanding the relationship
between amphetamine use and psychosis.
Prevalence and clinical presentation
Observations strongly suggest a relationship between the
intake of amphetamines and the development of acute
psychosis. First, early studies demonstrated that amphe-
tamines could trigger acute psychosis in healthy subjects.
In these studies, amphetamine was given in consecu-
tively higher doses until psychosis was precipitated, often
after 100–300 mg of amphetamine [20-23]. The symp-
toms subsided within 6 days. The effect was blocked by
the use of anti-psychotics [24]. Not all the subjects in
these studies became psychotic, as some had to be
removed from the experiment because of health risks
caused by elevation of heart rate, blood pressure or body
temperature. Secondly, psychosis has been viewed as an
adverse event, although rare, in children with ADHD
who have been treated with amphetamine [25-30].
Thirdly, drug-induced psychosis has been reported in
8–46% of regular users of amphetamines [31-37]. The
wide variation is probably due to different populations
being studied, gender [38] and the method and dur-
ation of amphetamine use [39]. It may also depend on
the instruments used to assess psychosis, e.g. self-
report [36] vs. formal diagnostic instruments [31,40].
Lastly, there is a positive correlation between amphet-
amine availability at a community level and the inci-
dence of psychosis in the same population [41-44].
Amphetamine has a terminal elimination half life (T½)
of 12–15 hours [45] and is often taken several times over
the course of many days in runs or binges [46-49]. There
is clinical evidence that such binges may end in psych-
osis. Surprisingly, it is poorly understood [1,50], whether
such psychosis is due to amphetamine use per se
(amount over time, amount on one occasion or the
length of the current binge), vulnerabilities in the user
or both. It could be that psychosis occurs because of
the sleep deprivation that follows amphetamine use, or
because of other factors at the end of a binge. Users will
often end their binge by using sedating drugs like alco-
hol, benzodiazepines, opiates or cannabis. This could be
viewed as self-medication [51] and may be one reason
why users often develop problems with several drugs.
Only a weak relationship has been reported between
psychotic symptoms and the level of amphetamines in
the blood of psychotic patients [51,52]. This could be
because acute blood levels at the end of a binge are a
poor representation of overall amphetamine exposure,
but it could also be because individual vulnerability,
rather than level of amphetamine exposure, is the critical
risk factor for developing acute psychosis.
The symptoms of psychosis induced by amphetamines
are very similar to those of acute schizophrenia spectrum
psychosis and include: lack of concentration, delusions of
persecution, increased motor activity, disorganization of
thoughts, lack of insight, anxiety, suspicion and auditory
hallucinations [21,22,53]. Some studies have suggested
differences with more pronounced grandiosity and visual
hallucinations [52,54]. The thought disorders that occur
in schizophrenia characterized by a splitting and loosen-
ing of associations, a concreteness of abstract thought,
and an impairment in goal-directed thought, may be less
prominent in amphetamine induced psychosis [55].
However, distinguishing the two types of psychosis on
the basis of acute symptoms is probably very difficult
[56]. The similarities between the two conditions are, in
fact, so pronounced that this has been used as an argu-
ment for using amphetamine-induced psychosis as a
model for primary psychotic disorders [21,54,57-59].
In contrast to schizophrenic psychosis, acute psychosis
induced by amphetamines seems to have a faster recov-
ery [60-63], and appears to resolve with abstinence,
although the recovery may be incomplete [43]. Japanese
researchers have argued that psychosis induced by
amphetamines could, in fact, be of much longer dur-
ation, up to several years [64-66]. This research
describes spontaneous psychotic relapses in the long
term after remittance of psychosis (“flashbacks”), a
phenomenon acknowledged in the popular folk culture
in the USA and Europe, but much less researched.
Stressful situations seem to trigger such flashbacks in
susceptible individuals and several vulnerability factors
have been identified, e.g. a family history of psychosis
[67-70]. It is difficult to distinguish the Japanese chronic
amphetamine psychosis from a primary psychosis trig-
gered by the use of amphetamines [64], although it has
been claimed that they constitute separate entities.
Risk factors and acute vs. chronic psychosis
In animal models, there is sensitization to the rewarding
effects of amphetamines (e.g. [71]). Sensitization is also
seen in human subjects [72]. There is reason to believe
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that an earlier psychosis involves a risk of future psych-
otic episodes due to this sensitization [43,73-75], or pos-
sibly to the development of dopaminergic super
sensitivity [76,77]. Psychosis may be precipitated acutely
by amphetamine due to its effects on dopaminergic ac-
tivity in the CNS [46]. In the longer term, the neurotoxic
effects of the drugs on serotonin and dopamine neurons
[78] and dopamine transporters [79] may play a role.
Amphetamine sensitization seems to cause dysregulation
of dopamine by the ventral subiculum [80]. There is an
over-expression of the dopamine receptor, subtype 2
(DRD2) [81] and a higher sensitivity of DRD2 to the
effects of amphetamines in vulnerable individuals [82].
In addition to the increased risk of psychosis following
the use of amphetamines in people who have experi-
enced amphetamine-induced psychosis previously,
patients with schizophrenia [83] and schizotypal person-
ality traits [74,84] may more readily become psychotic
after the use of amphetamines. Other risk factors for
psychosis may include amphetamine use disorders (abuse
and dependence), the presence of other psychiatric disor-
ders (primarily attenuated psychosis syndrome, personal-
ity disorders and affective disorders), early cognitive
dysfunction (such as those found in the prodromal states
of schizophrenia), family history of mental disorder and
the use of other drugs like opiates, benzodiazepines,
cannabis and alcohol [37,67,74,75,85-87].
Several susceptibility genes have been found in com-
mon for amphetamine-induced psychosis and schizo-
phrenia [32,58]. These genes increase the risk both for
becoming psychotic and for a poorer clinical course of
the disease. Studies in Japan also indicate that primary
and drug induced psychosis may be genetically linked.
Relatives of methamphetamine-users with a lifetime his-
tory of amphetamine psychosis are 5 times more likely
to have schizophrenia than methamphetamine-users
without a history of psychosis [85]. Patients with schizo-
phrenia and those with psychosis induced by ampheta-
mines both show significantly increased peripheral plasma
levels of norepinephrine compared to methamphetamine
users who do not have psychosis, and to non-using conrols
[65,88]. This seemingly common vulnerability is import-
ant considering the difficulties in distinguishing between
the two conditions in the long term.
The precipitation of psychosis by amphetamines in
healthy subjects can be blocked by anti-psychotics
[24,89]. Similarly, psychotic symptoms caused by amphe-
tamines can, like acute schizophrenic psychosis, be trea-
ted with anti-psychotics [90]. A Cochrane review from
2009 [91] identified only one randomized controlled trial
of treatment for psychosis induced by amphetamines
which met the criteria for included studies. It showed
that both olanzapine and haloperidol in clinically rele-
vant doses were effective in treating psychotic symptoms
[92]. One problem with using anti-psychotics could
be that such drugs have a tendency to block the DRD2,
potentially increasing anhedonia that could, in turn,
cause a greater vulnerability to relapse into drug abuse.
Some studies indeed point in this direction [93-95]. The
use of alternative therapeutic drugs, such as benzodiaze-
pines, will reduce the chance of extra pyramidal adverse
effects [96] and decrease the risk of intoxication [97].
However, one argument against this strategy is that anti-
psychotics seem to protect against the neurotoxic effects
of amphetamines [98,99].
To further complicate the situation, it seems that up
to 25% of those initially diagnosed with drug induced
psychosis after some years develope a primary psychotic
disorder [100], and even higher figures when looking at
methamphetamine induced psychosis [67]. This leaves
us with a dilemma - how valid is a diagnostic construct
of amphetamine induced psychosis? Such a term sug-
gests the assumption that this type of psychosis can be
induced in individuals otherwise not susceptible to, e.g.
schizophrenia or other primary psychotic disorders. The
ambiguity and difficulties of this diagnosis are reflected
in a recent review where the authors suggest the alterna-
tive term “substance-associated psychosis” and state that
there is a dearth of research that rigorously examines
the validity of the diagnostic criteria across substances
[101]. These researchers identified 18 papers that specif-
ically focused on delineating the clinical characteristics
or outcomes of individuals diagnosed with substance-
induced psychosis. Seven of these papers focused on
stimulants (amphetamines and cocaine), but only one
had a 1 year follow-up assessment.
Also for other substances of abuse with a tendency to
cause psychosis there have been similar discussions. It
has long been recognized that the use of cannabis in
early adolescence increases the risk of later development
of psychosis and schizophrenia [102,103]. Because the
drug intake takes place many years before the diagnosis
of schizophrenia it has been argued that this cannot be a
case of reversed causality [104]. There are however some
arguments in the opposite direction. Firstly, even with a
formidable increase in the use of cannabis in the popula-
tion, no increase in the incidence of schizophrenia has
been observed [105]. Secondly, it has been shown that
patients with schizophrenia may have their psychosis
triggered by lower intake of cannabis than healthy
volunteers [106]. Lastly, we do not know when a psych-
otic disorder starts to develop. It may be that it starts
long before the initial psychotic symptoms, opening for
the possibility of reversed causality, even when intake of
cannabis takes place years before first psychotic episode
[104]. The present agreement in the field seems to be
that cannabis can precipitate psychosis in vulnerable
individuals, an agreement that closely resembles our
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suggested model. The similarities between amphetamines’
and cannabis’ risk of being associated with later psychosis
is further supported by a newly published record linkage
study [107].
A model for the relationship between psychosis induced
by amphetamines and primary psychotic disorder
The similarities between acute schizophrenic psychosis
and psychosis following the use of amphetamines are
so pronounced that the latter has been suggested as a
model for schizophrenia [58,108]. However, it remains
unresolved whether the relationship between amphe-
tamines and psychosis is explained by drug exposure
(amphetamine-induced psychosis), amphetamines use trig-
gering a primary psychotic disorder or both. Although
psychosis may be induced by amphetamine in healthy
individuals, not all subjects become psychotic by the
doses of amphetamines allowed in the experiments.
Some, but not all, individuals using amphetamines have
experienced psychotic episodes, and a few have experi-
enced psychosis as an adverse event during stimulant
treatment. Is this a result of differences in amphetamine
exposure or differences in vulnerability? Furthermore,
psychosis is precipitated by a lower dose of ampheta-
mines in individuals with primary psychosis and may
be blocked by the use of anti-psychotics. Finally, there
seem to be many genetic and physiological similarities
between amphetamine-induced psychosis and acute schi-
zophrenic psychosis, suggesting that vulnerability may play
a significant role in the occurrence of amphetamines-
induced psychosis.
In this context, we hypothesize that the relationship
between amphetamine-induced psychosis and primary
psychosis can be viewed within the framework of a trad-
itional vulnerability stress paradigm (Figure 1). Exposure
to amphetamines should be viewed as a stressor in the
acute phase for the vulnerable individual in a dynamic
way; for individuals with lower vulnerability higher doses
of amphetamines are needed, whereas individuals with
higher vulnerability require lower doses to precipitate
acute psychosis. In addition, due to their sensitizing
effects, amphetamines may also play a role in the devel-
opment of vulnerability. Repeated use of amphetamines
could increase vulnerability, thereby increasing the
chances of developing psychotic symptoms even in the
absence of (acute exposure to) amphetamines. Thus,
primary psychotic disorder and psychosis precipitated by
amphetamines need not be considered as two separ-
ate phenomena, but as two phenomena interlinked in a
dynamic way.
Taking such a view may have some important clinical
implications. Patients diagnosed with drug induced
psychosis following intake of amphetamines should be
monitored more closely, in particular for signs of a
chronic development. Any further use of amphetamines
should be strongly discouraged, since it would constitute
an acute stressor that could precipitate psychosis and
increase the individual’s vulnerability to developing a more
chronic psychotic disorder. This model also provides a
rationale for future studies of preventive anti-psychotic
treatment, including psycho-social, psycho-educational
and possibly also pharmacological interventions to de-
crease vulnerability, in the same way as is recommended
for individuals with a primary psychotic disorder.
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Figure 1 The relationship between amphetamine use and the development of psychosis can be understood with a traditional stress/
vulnerability paradigm. Some users of amphetamine will not develop psychosis even using high amounts, while others will develop psychosis
with little or no exposure.
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